Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis - Wikidata - awgldk - TriplyDB

Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis

Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis

http://www.wikidata.org/entity/Q28288576

about

Interventions for American cutaneous and mucocutaneous leishmaniasis Immunoregulation in human American leishmaniasis: balancing pathology and protection Mucosal leishmaniasis: an underestimated presentation of a neglected disease Antiparasitic therapy Dolabelladienetriol, a compound from Dictyota pfaffii algae, inhibits the infection by Leishmania amazonensis Ex vivo host and parasite response to antileishmanial drugs and immunomodulators Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis Advances in the treatment of cutaneous leishmaniasis in the new world in the last ten years: a systematic literature review.Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period.Macrophages participate in host protection and the disease pathology associated with Leishmania braziliensis infection.Leishmaniasis: an update of current pharmacotherapy.Immunoregulatory and Effector Activities in Human Cutaneous and Mucosal Leishmaniasis: Understanding Mechanisms of Pathology.Interventions for American cutaneous and mucocutaneous leishmaniasis: a systematic review update.An update on pharmacotherapy for leishmaniasis Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide Reappraisal of the immunopathogenesis of disseminated leishmaniasis: in situ and systemic immune response Cutaneous leishmaniasis: recent developments in diagnosis and management Development of cutaneous leishmaniasis after leishmania skin test.Effect of TNF-α production inhibitors on the production of pro-inflammatory cytokines by peripheral blood mononuclear cells from HTLV-1-infected individuals Age modifies the immunologic response and clinical presentation of American tegumentary leishmaniasis.The Role of Nitric Oxide and Reactive Oxygen Species in the Killing of Leishmania braziliensis by Monocytes from Patients with Cutaneous Leishmaniasis.A proposed new clinical staging system for patients with mucosal leishmaniasis.Characterization of Neutrophil Function in Human Cutaneous Leishmaniasis Caused by Leishmania braziliensis Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil Recent developments leading toward a paradigm switch in the diagnostic and therapeutic approach to human leishmaniasis Functional dichotomy of dendritic cells following interaction with Leishmania braziliensis: infected cells produce high levels of TNF-alpha, whereas bystander dendritic cells are activated to promote T cell responses.Treatment of cutaneous leishmaniasis in travelers 2009.Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline.Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Pentoxifylline and its applications in dermatology.Potential benefits of pentoxifylline on wound healing.Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art.Enhanced photodynamic leishmanicidal activity of hydrophobic zinc phthalocyanine within archaeolipids containing liposomes Chemotherapy of leishmaniasis: present challenges.Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of Leishmania (Viannia) braziliensis.In Vitro Immunomodulatory Activity of a Transition-State Analog Inhibitor of Human Purine Nucleoside Phosphorylase in Cutaneous Leishmaniasis.

P2860

Q24241646-C2580964-900C-4B3F-8F87-30075C426B66 Q26850280-A0A715C3-5518-451B-80CA-F9480E2A6DAD Q26998036-CC3054D5-0CDA-4B76-8FE0-FB0B2802E868 Q28239164-6DE63E7B-5A47-43C4-8036-3621E93D736D Q28483511-DE976E44-C7AF-47DE-BCEC-4D0C4427EB49 Q28547648-B1B934EF-E43D-4FC0-9E2A-0A51C99FDDBF Q30275257-255CFBA5-515D-49AF-A394-8362F895808B Q33719037-74F05D69-CC8E-47E3-AC69-B81B6F0F5B9A Q33955466-DA72F005-C914-4138-8234-B6A9858363ED Q34189150-4310C468-6998-441C-BA4B-A56C9D9F9B76 Q34212620-3F057ADF-8DE2-4009-84B1-A61870DE101B Q34318765-D591047B-D8C3-4283-973B-EED9C18165DA Q34624834-E424DA88-B759-48F9-949E-2309490AB6B7 Q34700686-D6DCDDD7-2537-4257-9C4B-17F63FFFA3B7 Q34945204-2C3B3B08-8540-460C-9C4E-033A71E6A2E5 Q35160905-4723F8B6-F107-4EA3-9D65-E219C6605877 Q35168283-9DD079EE-8273-4126-8283-C3C14750841E Q35187729-7F16FFAF-5660-4BAF-AC07-BFD8B4C01B64 Q35581923-4DBFF050-1E33-46FA-83B2-89A711C13F49 Q35663886-CBFDE63A-FD1F-430C-BC5A-36C12055434F Q35692504-62D4A39F-F29C-4A37-BC6F-26E8515D03E5 Q35913098-AD30917A-124C-4D22-BDAD-285E5A51F3AE Q35989712-FFC60D0B-0621-418C-A0A7-D603ABDB5E40 Q36014374-0C50EB0C-FE0F-4CAE-A077-2213046E27AE Q36569120-6039D104-F3CE-496A-8D54-35C6D21ED16C Q37251607-D9E01A21-B4B6-43EF-A795-FD8E019AA932 Q37367783-184E4E83-C972-490D-88CD-55926757415A Q37428084-E610675C-BEF6-4831-B5A6-56490C13C8C5 Q37680694-E9C86A40-BF2F-4209-8D01-0FF6FF3D7DD5 Q37693923-67D42218-377C-4124-8201-D47889E35474 Q38156421-C803DCE0-55D4-4850-BF9A-8C9486A432E7 Q38195310-D874B1BC-2653-429C-9432-34F6E96CFA9E Q38205451-6BB7A983-A34E-47DB-93E6-724389F04656 Q38268117-FCF04D1B-200E-4857-8EBC-C778D77A178D Q38630692-C70E3491-5B5A-4CA2-B6C5-7C71224F09FC Q38939544-263677DD-FA88-42AD-BA36-1EF86D15B906 Q38973386-0F920684-0275-4E6D-8B8D-5FD40AF39083 Q39011875-FE137A82-746A-4EC6-BAF3-B2AF73E6A813 Q40128507-BD88C4AF-34BB-46BE-A1CA-3D2C48FB1FAC Q41448585-9435544B-467B-4DA7-B447-E6F7C8998699

P2860

Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis

http://www.wikidata.org/entity/Q28288576

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@ast

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@en

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@nl

type

label

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@ast

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@en

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@nl

prefLabel

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@ast

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@en

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@nl

P1433

Q28288576-902BDE7A-FF99-4DAE-BEDC-AA051195517A

P1476

Q28288576-53BC68B1-8CDB-448E-813D-E7AE0B941D18

P2093

Q28288576-57C1BF88-9A34-4018-8EBB-62917029D1A8

Q28288576-757DE34D-C830-4792-8634-32A9C8BF9F94

Q28288576-9BDB5215-4134-4EC7-88E9-CEE608B09552

Q28288576-D51A04B1-DBEA-4AAC-A121-64B5F1D87A26

Q28288576-E137398A-2E01-41C8-8627-E732E39BAF5F

Q28288576-F6E414C5-1934-4B8B-897D-C37B1D16EEDE

Q28288576-FE1F7FAB-8442-4646-8571-297047711480

P304

Q28288576-7A07A511-3E71-4991-AC2C-C7F4565DC64A

P31

Q28288576-852EEFC6-1087-4620-AE6B-2D57B7C4FA1B

P3181

Q28288576-2896870F-9564-49B3-A9C1-0BCBC92E04E8

P356

Q28288576-1EE45912-BCDA-4F61-A2F2-F8BED51DCA57

P407

Q28288576-2EEF8D7F-4C82-4F08-833F-57C135DE686B

P433

Q28288576-2AA830FC-12B5-496E-B2DA-FA04FA62B49E

P478

Q28288576-174A4D4D-874A-44EC-8BE2-471113DB36A9

P577

Q28288576-F691F886-66AE-447A-9E66-47B3A62D7DC3

P5875

Q28288576-8FB9275A-1A94-44C8-AFCF-87CF953F87FC

P698

Q28288576-9EB2571E-66B2-4EAC-A4AC-6346F1C4C00A

P3181

P356

P1433

Clinical Infectious Diseases

P1476

Oral pentoxifylline combined w ...... rial for mucosal leishmaniasis

@en

P2093

Edgar M Carvalho

http://www.w3.org/2001/XMLSchema#string

Heejung Bang

http://www.w3.org/2001/XMLSchema#string

Hélio Lessa

http://www.w3.org/2001/XMLSchema#string

John L Ho

http://www.w3.org/2001/XMLSchema#string

Luiz H Guimarães

http://www.w3.org/2001/XMLSchema#string

Marcus Lessa

http://www.w3.org/2001/XMLSchema#string

Paulo R L Machado

http://www.w3.org/2001/XMLSchema#string

P304

788-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1725655

http://www.w3.org/2001/XMLSchema#string

P356

10.1086/511643

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6501934

http://www.w3.org/2001/XMLSchema#string

P698

17304449

http://www.w3.org/2001/XMLSchema#string